MetaVia Inc. (MTVA)
| Market Cap | 7.84M -66.8% |
| Revenue (ttm) | n/a |
| Net Income | -14.45M |
| EPS | -3.72 |
| Shares Out | 6.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,592 |
| Open | 1.150 |
| Previous Close | 1.140 |
| Day's Range | 1.120 - 1.250 |
| 52-Week Range | 0.966 - 14.850 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 19.33 (+1,524.37%) |
| Est. Earnings | Nov 13, 2026 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Buy." The 12-month stock price target is $19.33, which is an increase of 1,524.37% from the latest price.
News
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract h...
MetaVia names Sarah Browne, M.D., as Chief Medical Officer
MetaVia (MTVA) announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12. Dr. Browne brings more than 20 years of experience spanning clinical development, regula...
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expert...
MetaVia reports results from DA-1726-derived radioactivity study
MetaVia (MTVA) announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body follow...
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-...
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE...
MetaVia Earnings release: Q2 2026
MetaVia released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
MetaVia Quarterly report: Q2 2026
MetaVia has published its Q2 2026 quarterly earnings report on August 6, 2026.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
MetaVia announces completion of dose titration in Phase 1 study of DA-1726
MetaVia (MTVA) announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and…
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ ...
MetaVia Transcript: Life Sciences Virtual Investor Forum
The company is advancing dual-action therapies for obesity and MASH, with promising early clinical results and a focus on strategic partnerships. Key data readouts and regulatory milestones are expected by year-end, positioning the firm for significant growth in competitive cardiometabolic markets.
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Ki...
MetaVia Transcript: Emerging Growth Conference 93
Recent conference presentations highlighted strong safety and PK data for DA-1726 and promising combination results for vanoglipol, especially with resmetirom and metformin. Cash reserves are expected to last through ongoing clinical trials into Q4.
MetaVia Transcript: AGM 2026
Five key proposals were presented, including director elections, auditor ratification, a reverse stock split, and an equity plan amendment. All proposals were approved, with voting results to be filed with the SEC.
MetaVia presents data at ADA supporting DA-1726, vanoglipel
MetaVia (MTVA) announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association’s 2026 Scientific Sessions, held June ...
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Wei...
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim...
MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations
MetaVia (MTVA) announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin – OXM – analog agonist targeting glucagon-like peptide-1 receptors, or GLP1R, and glucagon receptor...
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3...
3 Penny Stocks to Watch Now, 5/21/26
HCW Biologics ($HCWB), MetaVia ($MTVA), and Silexion Therapeutics ($SLXN) are the three penny stocks to watch on May 21, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to low-pri...
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of ...
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-st...
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Pat...
MetaVia Earnings release: Q1 2026
MetaVia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.